Company RXi Pharmaceuticals Corp Nasdaq
Equities
US74979C5013
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/12/19 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 15/17/15 |
Linda M. Mahoney
PRN | Corporate Officer/Principal | - | 10/22/10 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/12/19 |
Director/Board Member | 73 | 02/22/02 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 18/13/18 |
Jonathan Freeman
BRD | Director/Board Member | 56 | 07/17/07 |
Robert Ferrara
BRD | Director/Board Member | 73 | 01/19/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 4,591,700 | 4,564,638 ( 99.41 %) | 0 | 99.41 % |
Company contact information
Phio Pharmaceuticals Corp.
11 Apex Drive Suite 300A PMB 2006
01752, Marlborough
+508-767-3861
http://www.phiopharma.comSector
1st Jan change | Capi. | |
---|---|---|
+33.63% | 5.09TCr | |
-0.09% | 4.21TCr | |
+49.62% | 4.2TCr | |
-4.96% | 2.92TCr | |
+11.18% | 2.6TCr | |
-21.95% | 1.89TCr | |
+8.61% | 1.32TCr | |
+24.73% | 1.22TCr | |
+28.31% | 1.22TCr |